Tarsus Pharmaceuticals (TARS) Receivables (2020 - 2026)

Tarsus Pharmaceuticals' Receivables history runs 7 years deep, the most recent figure standing at $117.2 million for Q1 2026.

• In Q1 2026, Receivables rose 82.7% year-over-year to $117.2 million; the TTM figure through Mar 2026 stood at $117.2 million (up 82.7% YoY), while the FY2025 annual figure was $87.1 million, up 81.25% from the prior year.
• Receivables was $117.2 million for Q1 2026 at Tarsus Pharmaceuticals, up from $87.1 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $117.2 million in Q1 2026 to a low of $323000.0 in Q1 2022.
• Historically, Receivables has averaged $36.2 million across 5 years, with a median of $30.6 million in 2024.
• Biggest YoY gain for Receivables was 1691.0% in 2022; the steepest drop was 99.0% in 2022.
• A 5-year view of Receivables shows it stood at $3.6 million in 2022, then soared by 394.53% to $17.7 million in 2023, then surged by 171.31% to $48.1 million in 2024, then soared by 81.25% to $87.1 million in 2025, then jumped by 34.55% to $117.2 million in 2026.
• The last three Receivables figures came in at $117.2 million (Q1 2026), $87.1 million (Q4 2025), and $74.3 million (Q3 2025), per Business Quant data.